Gavreto® (pralsetinib) – Indication withdrawal
June 29, 2023 - Genentech and Blueprint Medicines announced that they are voluntarily withdrawing the indication of Gavreto (pralsetinib) for treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) who require systemic therapy.
Top